Baker2005
02 Mar 2018
Re: bid rumours rumour or no rumour, my view is this is somewhat oversold. Ought to be in the 3500 area IMO.I think the analysts have been overly negative .
tikky
01 Mar 2018
bid rumours i hear poss bid from US IMHOCheck reuters
nk1999
17 Feb 2018
Times- Tempus From 15/02:"Stay the course as pills keep workingShire is less than half the size of the UK pharmaceutical giants Astrazeneca and Glaxosmithkline but, with three $2 billion-a-year drugs across three therapy areas, it is much less dependent than its bigger rivals on single blockbuster drugs. This means that when the patents start to expire and competition from generic rivals is unleashed, the pain will be more bearable.However, Shire is not completely immune to the threat from copycats. Key products, including Lialda, used to treat ulcerative colitis, Vyvanse, which treats attention deficit hyperactivity disorder (ADHD), and Firazyr could face generic competition when their patents expire, starting from next year. Accounting for nearly $3.5 billion in revenue, they make up a significant portion of sales. Roche, a competitor, has recently launched a haemophilia treatment, Helimbra, that could dent Shire’s dominant position in this area and disrupt $3.8 billion of sales.The FTSE 100 company yesterday reported better than expected full-year results for 2017, with total revenues up by a third to $15.2 billion, ahead of forecasts of just under $15 billion. Growth was driven by strong trading in its immunology drugs division and good sales outside the US. The Trump administration’s recent tax cuts also helped to boost the bottom line.Despite this, investors seemed to be spooked by a warning from Flemming Ornskov, the chief executive, that profits could be lower this year, with sales growth in the mid-single digit range, owing to “the anticipated impact of generics”. Shire’s share price, which has fallen 31 per cent in the past 12 months, declined 1.4 per cent to £31.35½.That’s not the only pressure the company will face this year. It also warned yesterday that investment in its new plasma manufacturing plant in Georgia in the US will be a drag on overall growth.It is partly with pressures from generics in mind that Shire bought its leading American rival Baxalta in 2016 to strengthen its portfolio. It remains heavily indebted since the deal, with debt repayments likely to swallow up considerable cashflows in coming years. But on the positive side, the acquisition almost doubled Shire’s revenues and helped it to expand its international footprint as well as its expertise in advancing regulatory and commercial activities.One of Shire’s greatest strengths is its promising pipeline of drugs that could replace sales when its present bestsellers reach their patent cliffs. Recent products to emerge from the labs have been performing well, according to analysts at Hargreaves Lansdown, and have continued to broaden Shire’s range of therapy areas, with the dry eye treatment Xiidra a particular success.Last year Mr Ornskov said the company was considering spinning out its ADHD drugs division into a separate business, having decided that its rare diseases and neuroscience businesses had “distinct strategic priorities”. Roughly translated, this means that the neuroscience business needs more investment in R&D and less is needed for the rare diseases business, which has a strong pipeline. In preparation for this, Shire has pledged to publish separate financial metrics for each division from the first quarter of the current financial year.Yesterday Mr Ornskov said Shire would continue to weigh up the pros and cons of a split, adding that he would provide an update on the company’s thinking at the time of its next half-year results. He did not comment on rumours circulating late last year that Shire could be a takeover target, with Pfizer, the American group, reportedly a potential buyer.Advice HoldWhy Despite short-term headwinds, it has a deep pipeline of commercial and development-stage drugs"
nk1999
14 Feb 2018
Results [link] US GAAP diluted earnings per ADS outlook reflects anticipated amortization and integration costs.Full Year 2018 U.S. GAAP Outlook Non GAAP Outlook(1) Total product sales $14.9 - $15.3 billion $14.9 - $15.3 billion Royalties & other revenues $500 - $600 million $500 - $600 million Gross margin as a percentage of total revenue(2) 71.0% - 73.0% 73.5% - 75.5% Combined R&D and SG&A $5.2 - $5.4 billion $4.9 - $5.1 billion Net interest/other $450 - $550 million $450 - $550 million Effective tax rate 15% - 17% 16% - 18% Diluted earnings per ADS(3) $7.30 - $7.90 $14.90 - $15.50 ========== ========== ========== ========== =====So around USD 5.00 (~355p) EPS expected for this year?
emptywallet
26 Jan 2018
Re: Drop Seems pretty normal - every time I look it has dropped. Been a dog of a share for the last year or so at least.
nk1999
25 Jan 2018
Drop Big drops yesterday and today.Does anyone know what is going on here?nk
nk1999
22 Jan 2018
Rise today Up 50p today to 3511p. Extract from a bulletin:"Shire was on the front foot, boosted by news that French healthcare group Sanofi has agreed to buy US haemophilia specialist Bioverativ for $11.6bn."nk
Ripley94
17 Jan 2018
Re: Business Update Your response to Essential sound money is spot on.I've added you 
chopper89x
16 Jan 2018
Re: Business Update i'll bet my bottom dollar that there is a bid here before mid year
sound money
16 Jan 2018
Re: Business Update Essential,Forget the typo's no one with any sense worries.As to the substance, FCF looks solid. This appears to be purely about sentiment. Certainly not a reason to sell.M
EssentialInvestor
15 Jan 2018
Re: Business Update Has to give - this is the reason I don't post here much! -dyslexia coupled with a lack of Edit function on ii is not a good combo ).
EssentialInvestor
15 Jan 2018
Re: Business Update Agree with games and have posted similar thoughts elsewhere.However the market appears to be questioning the future levels of FCF.Now medium term something had to give. If Shire continues to generatesomewhere is the region of current FCF levels, the shares may be very cheapindeed IMV. That is the Big IF.Any thoughts/views appreciated.
The White Rider
09 Jan 2018
Re: Business Update Thanks for heads up on this Philanderer - I wasn't aware of the downgrade in revenue.
philanderer
08 Jan 2018
Re: Business Update Stated today .....Total revenue would reach US$17bn-18bn a year by 2020, a downgrade of its previous estimate of achieving US$20bn in revenue by that date
gamesinvestor
08 Jan 2018
Re: Business Update "I've committed as much as I want on this one."Moi aussi -- I underestimated the negative sentiment towards the company and the fact that few seem to have liked the Baxalta decision.Still if they keep throwing off £1Bn a quarter and paying down the debt, it should get recognised in the medium to long term.Disappointing though isn't it?Games
